MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 84 filers reported holding MERSANA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $42 | -44.7% | 12,869 | -30.2% | 0.01% | -28.6% |
| Q1 2023 | $76 | -47.2% | 18,437 | -24.8% | 0.01% | -50.0% |
| Q4 2022 | $144 | -99.9% | 24,533 | -22.6% | 0.01% | -33.3% |
| Q3 2022 | $214,000 | +122.9% | 31,698 | +52.1% | 0.02% | +90.9% |
| Q2 2022 | $96,000 | +41.2% | 20,836 | +22.4% | 0.01% | +37.5% |
| Q1 2022 | $68,000 | -66.7% | 17,027 | -48.2% | 0.01% | -65.2% |
| Q4 2021 | $204,000 | -24.2% | 32,871 | +65.8% | 0.02% | -14.8% |
| Q2 2021 | $269,000 | +195.6% | 19,821 | +27.7% | 0.03% | +50.0% |
| Q1 2020 | $91,000 | +378.9% | 15,524 | +31.9% | 0.02% | +500.0% |
| Q3 2019 | $19,000 | – | 11,772 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
| Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
| Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
| Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
| Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
| Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
| Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
| DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |